Genetic therapy breast cancer drug preparation method based on microfluidic chip

Abstract

The invention discloses a genetic therapy breast cancer drug preparation method based on microfluidic chip, which includes that: the method adopts biological molecules as computation medium to compute the cancer-related gene expression through biochemical reaction; when the result meets the requirement, the anti-cancer drug is automatically synthesized and released in targeted manner; the anti-cancer drug is complete suicide gene; the biological molecules used as computation medium are DNA molecules and / or enzyme; the oncogene related to breast cancer includes: C-erbB-2, EGFR, c-myc, ras, int-2, bcl-2, BAG-1, BCSG-2 and survivin; the cancer suppressor gene related to breast cancer includes P53, nm23, PTEN, Rb, P16, P21, CHEK2, BRCA1 and BRCA2. The invention can synthesize and release anti-cancer drugs for breast cancer on specified conditions; and the anti-cancer drugs are complete suicide gene. The method can be combined with the nanometer technology and micromachining technology to help improve the treatment effect.

Description

technical field [0001] The invention relates to computer science, molecular biology, medicine and microfluidic chip technology. In particular, it provides a method for preparing a medicine for gene therapy of breast cancer based on a microfluidic chip. Background technique [0002] Cancer is a genetic disease, and diagnosis and treatment at the genetic level are the most basic and accurate methods. Cell carcinogenesis is a process based on the activation of multiple proto-oncogenes and the inactivation of tumor suppressor genes. Therefore, in genetic diagnosis, it is often necessary to make a comprehensive judgment on the expression levels of multiple genes. At present, the diagnosis of cancer is often carried out in vitro, and it is far from reaching the single-cell level by judging the results of blood and tissue tests. Moreover, in vitro diagnosis and in vivo treatment are two relatively independent links, and anticancer drugs often cause greater damage to normal cells....

AI Technical Summary

Problems solved by technology

However, if this kind of DNA computer is to be further tested in vivo, there are still the following shortcomings: 1. All the biochemical reactions of the computer are carried out in test tubes. If the DNA computer needs to enter the body to perform functions, it must be carried by an effective carrier. DNA molecules and enzymes deliver them to the corresponding targets to prevent DNA molecules from being degraded before calculation. Obviously, test tubes cannot be such an effective carrier; And each calculation of a gene needs to introduce a variety of high-concentration exogenous molecules, which may affect the normal physiological functions of the cells; 3. The computer must enter the cell to perform its functions, which increases the difficulty of operation ; 4, the most important point, this computer uses restriction endonuclease (Fok I enzyme) to carry out enzymatic digestion reaction, restriction endonuclease only exists in lower organisms (such as bacteria, virus etc.), can be in specific position Dots can cut double-stranded DNA molecules and thus have the potential to affect the genomes of higher organisms

But it also has its disadvantages: the therapeutic gene is a random non-specific transfection virus antigen can induce the body to produce an immune response, which limits repeated use; recombinant adenovirus can cause transfection cell toxicity and cell death, which limits the time of gene expression; damage to cells

[0016] There are currently problems in breast cancer gene therapy: (1) lack of efficient and specific targeting vectors: it is required to reduce the potential tumorigenicity of viral vectors without damaging normal cells

(2) Controllability of gene expression: current research tends to use tissue and tumor-specific gene promoters to control target gene expression

Images